15 results about "Deficiency anemias" patented technology

The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.

In an iron (II) citrate monohydrate, identified by the formula FeC6H6O7-H2O ( Ferrous citrate monohydrate or iron citrate (II) monohydrate), obtained according to a particular production method, citric acid and elemental iron are bound in a molecular complex where the iron is agglomerated in the citrate which moves to a cyclic form and the iron is bound to the O groups of the carboxylic groups 1 and 3 through ionic bonds, forming two enantiomers, D and L (R and S), both perfectly water-soluble and highly assimilable by the human body. Formula (L) & Formula (D). With a different absorption mechanism from traditional iron molecules, said iron citrate monohydrate is usable in pharmaceutical and / or nutraceutical and / or food compositions, in particular in the treatment and prevention of iron deficiency anemias and in general of all diseases and disorders associated with iron deficiency. The effectiveness is proven by several examples.

The invention provides stem cell-derived apoptotic extracellular vesicles (ApoEVs) with an iron homeostasis regulation effect and application of the stem cell-derived apoptotic extracellular vesicles in preparation of a medicine for treating iron-deficiency anemia, and belongs to the technical field of biological medicines. The ApoEVs is an outer vesicle separated from apoptotic cells derived from human periodontal ligament stem cells, and can effectively recover the iron level in low-iron cells induced by DFOM, up-regulate the expression of iron storage protein and regulate the level of iron export protein, thereby improving the iron homeostasis of the cells. Meanwhile, the ApoEVs have good biocompatibility and safety, and a new strategy is provided for treatment of iron-deficiency anemia.

The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.

The present invention provides antibodies that bind to BMP6, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to BMP6. The antibodies of the invention are useful for inhibiting binding of BMP6 to the hemojuvelin receptor, thereby down-regulating transcription and expression of hepcidin, thus providing a means of preventing or treating an iron-deficiency anemia or an iron-deficiency related disorder. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of an iron-deficiency anemia or an iron-deficiency related disorder.

The invention discloses application of enteric microorganisms in medicines or health care products participating in black fungus melanin for combined treatment of iron-deficiency anemia, and belongs to the technical field of biology. In the invention, the intestinal microorganism ackermann bacteria and black fungus melanin are used for intragastric administration to treat iron-deficiency anemia mice, and a synergistic interaction effect is generated, so that the iron-deficiency anemia symptoms of the mice can be obviously improved. Compared with the prior art, the intestinal microorganisms can effectively improve blood routine indexes, iron metabolism indexes and inflammation indexes of IDA mice and repair colon injury in the process of treating iron-deficiency anemia by participating in black fungus melanin. The iron-supplementing prebiotic preparation is expected to be specifically applied to treatment of iron-deficiency anemia and further replace a traditional iron-supplementing agent to become a next-generation novel iron-supplementing prebiotic preparation, and a potential new strategy is provided for treatment of iron-deficiency anemia patients clinically.

The inventions relate to medicine and pharmaceutics and can be used in the treatment of iron-deficiency anemia. A method for producing a composition of water-soluble readily absorbable bivalent iron includes dissolving an organic reducing compound in water and adding a source of iron(II), wherein the molar ratio of the organic reducing compound to the iron(II) source is from approximately 3:1 to 10:1. A composition of water-soluble readily absorbable bivalent iron is produced using the claimed method, and a hermetically sealed ampoule is used in a method for delivering said composition. The result is the fast and effective treatment of iron-deficiency anemia in patients.

The invention discloses a combined biological agent and application thereof, and belongs to the technical field of biology. Amino acid and black fungus melanin are combined for intragastric administration to treat iron-deficiency anemia mice, a synergistic effect can be achieved, and the iron-deficiency anemia symptoms of the mice are remarkably improved. Compared with the prior art, the combined biological agent disclosed by the invention can be used for effectively improving blood indexes and intestinal tissue structures of mouse iron-deficiency anemia by regulating and controlling expression of iron transporter, so that the aim of improving symptoms of iron-deficiency anemia is fulfilled. The invention aims at finding a scientific, safe, small-toxic-side-effect and long-term-use iron-deficiency anemia treating agent which is expected to be specifically applied to treatment of iron-deficiency anemia and further replace a traditional iron supplementing agent to become a next-generation novel iron supplementing agent from raw materials with homology of medicine and food.

Ferrous fumarate, gellan gum and dextran sulfate are prepared into an ion-sensitive tablet, and the surface of the ion-sensitive tablet is subjected to enteric coating, so that the ion-sensitive tablet basically does not release iron elements in the stomach, and the ion-sensitive tablet is quickly converted into iron-containing gel when entering the intestinal tract, so that the iron-containing gel can be quickly dissolved in the intestinal tract. Further, slow and uniform release in intestinal tracts is realized, and stimulation of high-dose iron to gastrointestinal tracts is reduced; in addition, ferrous fumarate and Chinese herbal medicines are combined to form beneficial complementation, so that the dual purposes of supplementing iron and tonifying qi and blood are achieved, and the iron-deficiency anemia is effectively improved.

The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.

To provide a prophylactic and / or therapeutic agent for iron-deficiency anemia in a hypermenorrhea patient and / or a patient suffering from a hypermenorrhea-associated gynecologic disease.SOLUTION: According to the present invention, a prophylactic and / or therapeutic agent for iron-deficiency anemia in a hypermenorrhea patient and / or a patient suffering from a hypermenorrhea-associated gynecologic disease can be provided, which contains ferric citrate as an active ingredient.SELECTED DRAWING: None

The invention discloses application of artesunate in preparation of medicines and health care products for preventing and treating iron-deficiency anemia caused by iron absorption disorder and / or iron transport dysfunction, in-vitro experiments find that artesunate can target divalent metal transport protein (DMT1), DMT1 is oxidized through free radicals to form disulfide bonds, the space structure of DMT1 is changed, and the iron-deficiency anemia caused by iron absorption disorder and / or iron transport dysfunction is prevented. The iron transport function of the DMT1 protein is enhanced, so that the uptake of divalent iron by cells is effectively increased; animal experiments further prove that the artesunate can remarkably improve anemia symptoms of mice with iron-deficiency anemia, anemia related indexes of the mice are effectively recovered, and the iron content in red blood cells and livers is recovered to the normal level. In-vitro and in-vivo experiments prove the treatment effect of artesunate on iron-deficiency anemia, a new treatment scheme is provided for treatment of iron-deficiency anemia patients, and the indication types of artemisinin drugs are expanded.

Complex molecular units of ferrous bis-citrate monot art rate stable over time, which has optimal bioavailability, are obtained through a particular and simple synthesis method, and have the following structural formula M: STRUCTURAL FORMULA M Through a polymerization method, such complex molecular units of iron bis-citrate monotartrate form the monomers of a cyclic polymer structure having the following structural formula P: STRUCTURAL FORMULA P where the iron content per each mole of substance is equal to 50. 20% (w / w), and where the same iron has the dual role of bridging the two acids which move in a cyclic form and binding to the 0- groups of the carboxylic groups by means of dative covalent bonds, resulting in both intramolecular and intermolecular bonds. Such a cyclic polymer structure is usable in pharmaceutical, food, and / or nutraceutical composit ions, in particular in the treatment and prevention of iron deficiency anemias and, in general, all diseases or disorders associated with iron deficiency.

Use of artesunate in the preparation of a medicament for preventing and treating anemia. In vitro experiments have shown that artesunate can enhance the iron transport function of the DMT1 protein to increase iron ion uptake. In addition, animal experiments have demonstrated that artesunate can significantly improve anemia symptoms in mice with iron-deficiency anemia, effectively restore anemia-related indicators, and even restore the iron content in red blood cells and the liver to a healthy level.